BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Isarna Therapeutics

Isarna Therapeutics logo

Founded
1998
Patents
10
Clinical Trials
4
Publications
8

Technologies

Antisense Oligonucleotides

Isarna Therapeutics has an unmatched commitment to developing TGF-B inhibitors that stimulate the human immune system to effectively fight cancer. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.


Posts Mentioning This Company

Antisense Oligonucleotides Make Sense

  
Antisense oligonucleotides (ASOs) are short (about 12 to 25 nucleotides long), synthetic single strands of DNA or RNA that are complementary to a chosen sequence. They can alter RNA and reduce, restore, or modify protein expression. ASOs interact with proteins on the surface of cells and enter the cytoplasm. Then …
SHARE